Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VNZZZ
ADC Name
PF-06688992
Synonyms
GD3 ADC; PF 06688992; PF06688992
   Click to Show/Hide
Organization
Pfizer Inc.; Memorial Sloan-Kettering Cancer Center
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Phase 1
Antibody Name
Undisclosed
Antigen Name
Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase (ST8SIA1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
Puchem SID
402426011 , 472420097 , 440234698
TTD ID
D0JB9C
ChEBI ID
CHEMBL4594487
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT03159117
Phase 1
A phase 1 open-label dose escalation of GD3 ADC (PFIZER PF-06688992) in subjects with unresectable stage 3 or stage 4 malignant melanoma (b802wi209568).
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT03159117  Clinical Status Phase 1
Clinical Description A phase 1 open-label dose escalation of GD3 ADC (PFIZER PF-06688992) in subjects with unresectable stage 3 or stage 4 malignant melanoma (b802wi209568).
References
Ref 1 A Phase I Open-Label Dose Escalation of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568), NCT03159117

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.